144 related articles for article (PubMed ID: 16641432)
41. Antimicrobial activity of a novel peptide deformylase inhibitor, LBM415, tested against respiratory tract and cutaneous infection pathogens: a global surveillance report (2003-2004).
Watters AA; Jones RN; Leeds JA; Denys G; Sader HS; Fritsche TR
J Antimicrob Chemother; 2006 May; 57(5):914-23. PubMed ID: 16549511
[TBL] [Abstract][Full Text] [Related]
42. Synthesis and antibacterial activity of peptide deformylase inhibitors.
Huntington KM; Yi T; Wei Y; Pei D
Biochemistry; 2000 Apr; 39(15):4543-51. PubMed ID: 10758004
[TBL] [Abstract][Full Text] [Related]
43. Compensatory mutations in agrC partly restore fitness in vitro to peptide deformylase inhibitor-resistant Staphylococcus aureus.
Zorzet A; Andersen JM; Nilsson AI; Møller NF; Andersson DI
J Antimicrob Chemother; 2012 Aug; 67(8):1835-42. PubMed ID: 22577101
[TBL] [Abstract][Full Text] [Related]
44. In vitro activities of peptide deformylase inhibitors against gram-positive pathogens.
Wise R; Andrews JM; Ashby J
Antimicrob Agents Chemother; 2002 Apr; 46(4):1117-8. PubMed ID: 11897602
[TBL] [Abstract][Full Text] [Related]
45. Gepotidacin (GSK2140944)
Flamm RK; Farrell DJ; Rhomberg PR; Scangarella-Oman NE; Sader HS
Antimicrob Agents Chemother; 2017 Jul; 61(7):. PubMed ID: 28483959
[TBL] [Abstract][Full Text] [Related]
46. Potential utility of a peptide deformylase inhibitor (NVP PDF-713) against oxazolidinone-resistant or streptogramin-resistant Gram-positive organism isolates.
Jones RN; Moet GJ; Sader HS; Fritsche TR
J Antimicrob Chemother; 2004 May; 53(5):804-7. PubMed ID: 15056649
[TBL] [Abstract][Full Text] [Related]
47. Characterization of a novel fucose-regulated promoter (PfcsK) suitable for gene essentiality and antibacterial mode-of-action studies in Streptococcus pneumoniae.
Chan PF; O'Dwyer KM; Palmer LM; Ambrad JD; Ingraham KA; So C; Lonetto MA; Biswas S; Rosenberg M; Holmes DJ; Zalacain M
J Bacteriol; 2003 Mar; 185(6):2051-8. PubMed ID: 12618474
[TBL] [Abstract][Full Text] [Related]
48. In vitro activity of nemonoxacin (TG-873870), a novel non-fluorinated quinolone, against clinical isolates of Staphylococcus aureus, enterococci and Streptococcus pneumoniae with various resistance phenotypes in Taiwan.
Chen YH; Liu CY; Lu JJ; King CH; Hsueh PR
J Antimicrob Chemother; 2009 Dec; 64(6):1226-9. PubMed ID: 19833635
[TBL] [Abstract][Full Text] [Related]
49. Mode of action and biochemical characterization of REP8839, a novel inhibitor of methionyl-tRNA synthetase.
Ochsner UA; Young CL; Stone KC; Dean FB; Janjic N; Critchley IA
Antimicrob Agents Chemother; 2005 Oct; 49(10):4253-62. PubMed ID: 16189106
[TBL] [Abstract][Full Text] [Related]
50. Antimicrobial activity of the new macrolide flurithromycin against Haemophilus influenzae, Streptococcus pneumoniae, Streptococcus pyogenes, Branhamella catarrhalis and Staphylococcus aureus.
Nord CE; Lindmark A; Persson I
J Chemother; 1989 Jul; 1(4 Suppl):203-4. PubMed ID: 16312369
[No Abstract] [Full Text] [Related]
51. Acylprolinamides: a new class of peptide deformylase inhibitors with in vivo antibacterial activity.
Axten JM; Medina JR; Blackledge CW; Duquenne C; Grant SW; Bobko MA; Peng T; Miller WH; Pinckney T; Gallagher TF; Kulkarni S; Lewandowski T; Van Aller GS; Zonis R; Ward P; Campobasso N
Bioorg Med Chem Lett; 2012 Jun; 22(12):4028-32. PubMed ID: 22579486
[TBL] [Abstract][Full Text] [Related]
52. Flavimycins A and B, dimeric 1,3-dihydroisobenzofurans with peptide deformylase inhibitory activity from Aspergillus flavipes.
Kwon YJ; Sohn MJ; Kim CJ; Koshino H; Kim WG
J Nat Prod; 2012 Feb; 75(2):271-4. PubMed ID: 22329646
[TBL] [Abstract][Full Text] [Related]
53. In vitro activities of DX-619 and comparison quinolones against gram-positive cocci.
Wickman PA; Black JA; Moland ES; Thomson KS
Antimicrob Agents Chemother; 2006 Jun; 50(6):2255-7. PubMed ID: 16723599
[TBL] [Abstract][Full Text] [Related]
54. Peptide deformylase in Staphylococcus aureus: resistance to inhibition is mediated by mutations in the formyltransferase gene.
Margolis PS; Hackbarth CJ; Young DC; Wang W; Chen D; Yuan Z; White R; Trias J
Antimicrob Agents Chemother; 2000 Jul; 44(7):1825-31. PubMed ID: 10858337
[TBL] [Abstract][Full Text] [Related]
55. Mechanism of time-dependent inhibition of polypeptide deformylase by actinonin.
Van Aller GS; Nandigama R; Petit CM; DeWolf WE; Quinn CJ; Aubart KM; Zalacain M; Christensen SB; Copeland RA; Lai Z
Biochemistry; 2005 Jan; 44(1):253-60. PubMed ID: 15628866
[TBL] [Abstract][Full Text] [Related]
56. Identification of novel aminopiperidine derivatives for antibacterial activity against Gram-positive bacteria.
Lee HY; An KM; Jung J; Koo JM; Kim JG; Yoon JM; Lee MJ; Jang H; Lee HS; Park S; Kang JH
Bioorg Med Chem Lett; 2016 Jul; 26(13):3148-3152. PubMed ID: 27173797
[TBL] [Abstract][Full Text] [Related]
57. Role of the AcrAB-TolC efflux pump in determining susceptibility of Haemophilus influenzae to the novel peptide deformylase inhibitor LBM415.
Dean CR; Narayan S; Daigle DM; Dzink-Fox JL; Puyang X; Bracken KR; Dean KE; Weidmann B; Yuan Z; Jain R; Ryder NS
Antimicrob Agents Chemother; 2005 Aug; 49(8):3129-35. PubMed ID: 16048914
[TBL] [Abstract][Full Text] [Related]
58. Characterization of an eukaryotic peptide deformylase from Plasmodium falciparum.
Bracchi-Ricard V; Nguyen KT; Zhou Y; Rajagopalan PT; Chakrabarti D; Pei D
Arch Biochem Biophys; 2001 Dec; 396(2):162-70. PubMed ID: 11747293
[TBL] [Abstract][Full Text] [Related]
59. Discovery of a novel and potent class of FabI-directed antibacterial agents.
Payne DJ; Miller WH; Berry V; Brosky J; Burgess WJ; Chen E; DeWolf WE; Fosberry AP; Greenwood R; Head MS; Heerding DA; Janson CA; Jaworski DD; Keller PM; Manley PJ; Moore TD; Newlander KA; Pearson S; Polizzi BJ; Qiu X; Rittenhouse SF; Slater-Radosti C; Salyers KL; Seefeld MA; Smyth MG; Takata DT; Uzinskas IN; Vaidya K; Wallis NG; Winram SB; Yuan CC; Huffman WF
Antimicrob Agents Chemother; 2002 Oct; 46(10):3118-24. PubMed ID: 12234833
[TBL] [Abstract][Full Text] [Related]
60. Pharmacokinetic-Pharmacodynamic Evaluation of Gepotidacin against Gram-Positive Organisms Using Data from Murine Infection Models.
Bulik CC; Okusanya ÓO; Lakota EA; Forrest A; Bhavnani SM; Hoover JL; Andes DR; Ambrose PG
Antimicrob Agents Chemother; 2017 Feb; 61(2):. PubMed ID: 27872075
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
